Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | FLT4 | P35916 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273970 | 1.00 | CHUK (0.54) | CHUKCHEK1GSK3BCDK5CDK5R1 | |
| SCHEMBL21070513 | 0.86 | MAPT (0.49) | CHUKCHEK1GSK3BCDK5CDK5R1 | |
| SCHEMBL13598899 | 0.79 | CHEK1 (0.53) | CHEK1PTK6AURKAPARP1MEN1 | |
| SCHEMBL4958453 | 0.79 | CHEK1 (0.53) | CHEK1AURKAPARP1MEN1KMT2A | |
| SCHEMBL30273621 | 0.79 | CHUK (0.54) | CHUKCHEK1GSK3BCDK5CDK5R1 | |
| SCHEMBL4961015 | 0.79 | CHEK1 (0.53) | CHEK1ERBB2PTK6AURKAPARP1 | |
| SCHEMBL4961010 | 0.79 | CHEK1 (0.53) | CHEK1AURKAPARP1MEN1KMT2A | |
| SCHEMBL2628367 | 0.79 | ACHE (0.56) | CHEK1GSK3BGSK3AAURKAPARP1 | |
| SCHEMBL16011911 | 0.79 | CHUK (0.54) | CHUKCHEK1GSK3BCDK5CDK5R1 | |
| SCHEMBL30304796 | 0.79 | ACHE (0.56) | CHUKCHEK1GSK3BCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4629980-A1 | ANTIMICROBIAL COMPOUNDS | SRI International (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4539937-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | Prelude Therapeutics Incorporated (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20130306940-A1 | HETEROLEPTIC IRIDIUM COMPLEXES CONTAINING CARBAZOLE-IMIDAZOLE-CARBENE LIGANDS AND APPLICATION OF THE SAME IN LIGHT-EMITTING DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130306940-A1 | HETEROLEPTIC IRIDIUM COMPLEXES CONTAINING CARBAZOLE-IMIDAZOLE-CARBENE LIGANDS AND APPLICATION OF THE SAME IN LIGHT-EMITTING DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH PATENTS & SCIENTIFIC INFORMATION (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH PATENTS & SCIENTIFIC INFORMATION (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| WO-2011060867-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | MERCK PATENT GMBH (DE) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010025872-A2 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2010-03-11 | — | — | WO | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008016184-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHUK 258/4885CHEK1 851/4885GSK3B 663/4885 |
| US-20120232241-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUNDS FOR OLEDS | OCIAD2, OCIAD1, ODC1 | CHUK 4164/4885CHEK1 2363/4885GSK3B 4393/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHUK 258/4885CHEK1 851/4885GSK3B 663/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | CHUK 1286/4885CHEK1 2063/4885GSK3B 522/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | CHUK 3727/4885CHEK1 2633/4885GSK3B 1862/4885 |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | CHUK 186/4885CHEK1 1744/4885GSK3B 104/4885 |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | SRR, SRRM2, CRBN | CHUK 2332/4885CHEK1 3435/4885GSK3B 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.